European Journal of Surgical Oncology
Volume 33, Issue 1 , Pages 44-48 , February 2007

Identification of EGFR mutations in esophageal cancer

  • T. Sudo

      Affiliations

    • Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan
    • ,
  • K. Mimori

      Affiliations

    • Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan
    • ,
  • H. Nagahara

      Affiliations

    • Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan
    • ,
  • T. Utsunomiya

      Affiliations

    • Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan
    • ,
  • H. Fujita

      Affiliations

    • Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
    • ,
  • Y. Tanaka

      Affiliations

    • Saitama Cancer Center, 818, Komuro, Ina-machi, Saitama 362-0806, Japan
    • ,
  • K. Shirouzu

      Affiliations

    • Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
    • ,
  • H. Inoue

      Affiliations

    • Department of Surgery, Kurume University School of Medicine, 67 Asahi-machi, Kurume 830-0011, Japan
    • ,
  • M. Mori

      Affiliations

    • Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 977 27 1650; fax: +81 977 27 1651.

,Accepted 20 October 2006.

References 

  1. Cancer incidence and incidence rates in Japan in 1992–93: estimates based on data from seven population-based cancer registries. The Research Group for Population-based Cancer Registration in Japan. Jpn J Clin Oncol. 1998;28:641–647
  2. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21:2237–2246
  3. Wells A. EGF receptor. Int J Biochem Cell Biol. 1999;31:637–643
  4. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82:241–250
  5. Yoshida K, Kuniyasu H, Yasui W, et al. Expression of growth factors and their receptors in human esophageal carcinomas: regulation of expression by epidermal growth factor and transforming growth factor alpha. J Cancer Res Clin Oncol. 1993;119:401–407
  6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500
  7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139
  8. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493–2501
  9. Chou TY, Chiu CH, Li LH, et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res. 2005;11:3750–3757
  10. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306–13311
  11. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res. 2005;11:1167–1173
  12. Barber TD, Vogelstein B, Kinzler KW, et al. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N Engl J Med. 2004;351:2883
  13. Nagahara H, Mimori K, Ohta M, et al. Somatic mutations of epidermal growth factor receptor in colorectal carcinoma. Clin Cancer Res. 2005;11:1368–1371
  14. Guo M, Liu S, Lu F. Gefitinib-sensitizing mutations in esophageal carcinoma. N Engl J Med. 2006;354:2193–2194
  15. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, et al. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol. 2006;24:1612–1619
  16. Mimori K, Mori M, Inoue H, et al. Elongation factor 1 gamma mRNA expression in oesophageal carcinoma. Gut. 1996;38:66–70
  17. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53:2379–2385
  18. Hollstein MC, Smits AM, Galiana C, et al. Amplification of epidermal growth factor receptor gene but no evidence of ras mutations in primary human esophageal cancers. Cancer Res. 1988;48:5119–5123
  19. Lu SH, Hsieh LL, Luo FC, et al. Amplification of the EGF receptor and c-myc genes in human esophageal cancers. Int J Cancer. 1988;42:502–505
  20. Knight LA, Di Nicolantonio F, Whitehouse P, et al. The in vitro effect of gefitinib (“Iressa”) alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer. 2004;4:83
  21. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004;10:1212–1218
  22. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–2158
  23. Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, “Iressa”) on an expanded access study. Lung Cancer. 2004;44:221–230

PII: S0748-7983(06)00424-0

doi: 10.1016/j.ejso.2006.10.034

European Journal of Surgical Oncology
Volume 33, Issue 1 , Pages 44-48 , February 2007

Article Tools

* Image Usage & Resolution